NASDAQ:HZNP Horizon Therapeutics Public (HZNP) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$116.30▼$116.3050-Day Range$112.60▼$116.3052-Week Range$60.03▼$116.38VolumeN/AAverage Volume2.50 million shsMarket Capitalization$26.63 billionP/E Ratio62.19Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Horizon Therapeutics Public alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Horizon Therapeutics Public Stock (NASDAQ:HZNP)Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More Ad DTIHeard about the 72-Hour Profit Surge? Read this…One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…Click here now to get all the details. HZNP Stock News HeadlinesApril 27, 2024 | finance.yahoo.comHorizon Therapeutics Public Lim (HZNP)December 21, 2023 | seekingalpha.com5 Biotech Acquisition Targets To Accumulate In 2024July 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.November 16, 2023 | msn.comNasdaq On Horizon For Psyence Group: Psilocybin Therapeutics Division Forms New Business CombinationOctober 24, 2023 | chicago.suntimes.comHorizon Therapeutics cut jobs in Deerfield after Amgen acquisitionOctober 24, 2023 | msn.com350 Horizon Therapeutics workers to be laid off, mostly from Deerfield offices, following acquisition by AmgenOctober 6, 2023 | finance.yahoo.comRule 17(e) Announcement - Horizon Therapeutics plcOctober 5, 2023 | stocknews.com3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in OctoberJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.October 5, 2023 | stockhouse.comRule 17(d) Announcement - Horizon Therapeutics plcOctober 5, 2023 | finance.yahoo.comRule 17(d) Announcement – Horizon Therapeutics plcOctober 2, 2023 | finance.yahoo.comHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023September 26, 2023 | benzinga.comBoard Member at Horizon Therapeutics Exercises Options Worth $2.31MSeptember 26, 2023 | finance.yahoo.comHorizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care IndustrySeptember 19, 2023 | finance.yahoo.comHorizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 ListSeptember 19, 2023 | finance.yahoo.comHealth care: FTC Chair Lina Khan to crack down on 'below radar' dealsSeptember 13, 2023 | finance.yahoo.comQ32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia AreataSeptember 5, 2023 | finance.yahoo.comHorizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of ArrangementSee More Headlines Receive HZNP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HZNP CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone(531) 772-2100Fax224-383-3001Employees2,115Year Founded2008Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio62.19 Forward P/E Ratio27.76 P/E Growth3.96Net Income$521.48 million Net Margins12.02% Pretax Margin12.18% Return on Equity20.46% Return on Assets11.52% Debt Debt-to-Equity Ratio0.48 Current Ratio4.27 Quick Ratio4.09 Sales & Book Value Annual Sales$3.63 billion Price / Sales7.34 Cash Flow$7.05 per share Price / Cash Flow16.49 Book Value$22.38 per share Price / Book5.20Miscellaneous Outstanding Shares228,990,000Free Float223,957,000Market Cap$26.63 billion OptionableOptionable Beta1.03 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Timothy P. Walbert (Age 56)Chairman, Pres & CEO Comp: $3.5MMr. Aaron L. Cox (Age 40)Exec. VP of Fin. & CFO Comp: $1.36MMr. Sean M. Clayton J.D. (Age 44)Exec. VP & Gen. Counsel Comp: $7.03MMr. Andy Pasternak (Age 52)Exec. VP & Chief Strategy Officer Comp: $1.4MDr. Elizabeth H.Z. Thompson Ph.D. (Age 48)Exec. VP of R&D Comp: $3.66MMr. Patrick McIlvenny (Age 44)Sr. VP & Chief Accounting Officer Ms. Tina E. VenturaSr. VP & Chief Investor Relations OfficerMr. Geoffrey M. Curtis (Age 48)Exec. VP of Corp. Affairs & Chief Communications Officer Ms. Keli WalbertExec. VP & Chief Marketing OfficerMs. Jane GonnermanSr. VP of Corp. Devel. & Chief of Staff, Office of the CEOMore ExecutivesKey CompetitorsAlexion PharmaceuticalsNASDAQ:ALXNMyoKardiaNASDAQ:MYOKMirati TherapeuticsNASDAQ:MRTXBristol-Myers SquibbNYSE:BMYZoetisNYSE:ZTSView All Competitors HZNP Stock Analysis - Frequently Asked Questions How were Horizon Therapeutics Public's earnings last quarter? Horizon Therapeutics Public Limited (NASDAQ:HZNP) issued its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.08. Horizon Therapeutics Public's revenue was up 7.8% on a year-over-year basis. What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO? 70 employees have rated Horizon Therapeutics Public Chief Executive Officer Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among the company's employees. Does Horizon Therapeutics Public have any subsidiaries? Horizon Therapeutics Public subsidiaries include these companies: Viela Bio Inc., Curzion Pharmaceuticals Inc., River Vision Development Corp., Raptor Pharmaceuticals, Hyperion Therapeutics, Vidara Therapeutics, Horizon Medicines LLC, and more. What other stocks do shareholders of Horizon Therapeutics Public own? Based on aggregate information from My MarketBeat watchlists, some other companies that Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD) and Tesla (TSLA). This page (NASDAQ:HZNP) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Horizon Therapeutics Public Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Horizon Therapeutics Public With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.